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Introduction 
Carcinoid was first characterized by 
Lubarsh in 1888.1 However, Ranson is given 
credit for the first description of a carcinoid 
of the ileum in 1890.2 The term ‘karzinoide’ 
was used first by Oberndorfer in 1907 to 
describe tumors that behaved in a more 
indolent fashion than typical adeno-
carcinomas.3 In 1928, Masson stated that 
carcinoids should be considered as 
endocrine tumors since the malignant 
chromaffin or Kulchitsky cells in this 
disease exhibit amine uptake and 
decarboxylation characteristics.4 In 1930, 
Kramer grouped carcinoid tumors with 
cylindromas as bronchial adenomas because 
of their good prognosis compared with 
bronchogenic carcinoma.5 In 1972, Arrigoni 
and associates6 designated a subset of 
carcinoid adenomas that were more 
aggressive as "atypical".  
Bronchial carcinoid is a rare cause of 
pulmonary neoplasms accounting for about 
1-2% of all pulmonary malignancies7 and 
unique in the fact that it has neuroendocrine 
differentiation on histology. The incidence 
of carcinoid tumors varies with gender, age, 
and race. The overall incidence in the United 
States is estimated to be two cases per 
100,000 people.8 Carcinoid tumors often are 
diagnosed in a person’s fifth or sixth decade 
of life. Except in appendiceal and broncho-
pulmonary sites, African Americans have a 
higher incidence than other ethnic groups.9 
It is slightly more common in females (55%  
 
 
of all cases) than males.8 Seventy-four 
percent of carcinoid tumors originated in the 
gastrointestinal tract; the second most 
frequent site was in the tracheobroncho-
pulmonary tree with 25%.8 Bronchial 
carcinoids have a relatively indolent course 
and good prognosis if treated, although they 
do have malignant potential,10 therefore, it is 
important to recognize and treat them as 
soon as possible.  
 
Case Report 
A 46-year-old healthy Caucasian female 
presented to her primary care physician 
(PCP) two years prior for an episode of 
sporadic hemoptysis consisting of 1-2 
teaspoons of bright red blood without 
symptoms of cough, fever, or chills. 
Laboratory studies and chest x-rays were 
done at the PCP’s office and did not suggest 
any pathology. No further workup was done. 
Two years later, she presented to the 
PCP’s office again with two episodes of 
hemoptysis about one week apart. The 
patient did not have any systemic signs of 
anorexia, weight loss, fever, chills, cough, 
sputum production, or chest pain. Computed 
tomography (CT) of the chest showed a 17 x 
19 mm nodule in the left perihilar region 
(Figure 1). She was referred to the 
pulmonology service because of recurrent 
episodes of hemoptysis and CT evidence of 
a nodule.  
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Figure 1. Chest x-ray shows a left perihilar 
17 x 19 mass (arrow). 
 
A flexible bronchoscopy was performed 
electively. During bronchoscopy, an 
obstructing lesion at the bifurcation of left 
bronchus was found (Figure 2). Endo-
bronchial brushings and multiple biopsies 
from the mass showed cells to be consistent 
with carcinoid features with no pleo-
morphism (Figure 3) and staining for neuron 
specific enolase (NSE; Figure 4).  
The patient subsequently underwent 
radiotherapy to decrease the tumor size and 
the sleeve resection of the tumor. The 
patient has been doing well since. 
 
 
Figure 2.  Bronchoscopy showed typical 
finding of a solitary intraluminal mass 
(arrow).  
 
Discussion 
Carcinoid tumors are derived from 
dispersed neuroectodermal cells. They are 
neoplasms of  peptide- and amine-producing  
 
Figure 3. Pathology slide shows the 
carcinoid cell nests. 
 
 
Figure 4. Positive staining is shown for 
neuron specific enolase. 
 
cells, and their variable hormone profiles are  
based on the site of origin.11 Carcinoid 
tumors can be divided into foregut derived, 
midgut derived, and hindgut derived.9 
Foregut carcinoids include those derived 
from the stomach, duodenum, thymus, and 
bronchus. Carcinoid syndrome is rare in 
foregut and hindgut derived tumors because 
the tumor cells of foregut and hindgut origin 
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do not have enzyme dopa decarboxylase to 
convert 5-hydroxytryptophan to serotonin. 
Carcinoid syndrome, if present, is atypical in 
these tumors. It is mainly the midgut derived 
which presents with typical carcinoid 
syndrome.  
Bronchopulmonary carcinoid tumors 
account for approximately 25% to 30% of 
all carcinoid tumors.5 The annual incidence 
rates of bronchial carcinoids are 0.52 and 
0.89 per 100,000 population in males and 
females, respectively (the corresponding 
values for black males and females are 0.39 
and 0.57, respectively).5  
Pulmonary carcinoid tumors are thought 
to arise from Kulchitsky cells/neuro-
ectodermal cells disseminated throughout 
the bronchopulmonary mucosa.6 Histo-
logically, bronchial neuroendocrine tumors 
are divided into four distinct histologic 
types. These include typical bronchial 
carcinoid, atypical carcinoid, large cell 
neuroendocrine carcinoma, and small cell 
neuroendocrine carcinoma.12 Representing 
nearly two-thirds of pulmonary carcinoids, 
well-differentiated neuroendocrine tumors 
of the lungs and bronchi (typical carcinoids) 
are composed of cytologically bland cells 
that exhibit minor cellular atypia and rare 
mitoses.12 Based on the 2004 WHO 
classification, these tumors must 
demonstrate fewer than two mitoses per 10 
high power fields (10 HPF), lack necrosis, 
and be equal to or greater than 5 mm.13  
Foregut carcinoids (including those 
arising in the lung) generally have a low 
serotonin content. This is because foregut 
carcinoids often lack aromatic amino acid 
decarboxylase and cannot make serotonin 
and its metabolites (including 5-HIAA). 
Although they can produce a variety of other 
peptides and hormones within the cell 
(gastrin releasing peptide, 5-hydroxy-
tryptophan, and chromogranins), bronchial 
carcinoids only occasionally secrete 
bioactive amines. As a result, elevated 
plasma or urinary hormone levels rarely are 
detected. Serum levels of chromogranin A 
are sensitive but a non-specific marker, its 
levels being lower with bronchial carcinoids 
than with other neuroendocrine tumors. 
Measurement of serum CGA levels, 
however, can be useful to follow disease 
activity in the setting of advanced or 
metastatic disease.14 
Bronchial carcinoids usually present in 
the fifth decade of life and demonstrate a 
relatively indolent disease course. Patients 
may present with recurrent pneumonia, 
cough, wheezing, hemoptysis, and chest 
pain.15 Symptoms are highly variable and 
often present years before diagnosis. 
Cushing’s syndrome occurs in 2% of 
patients; moreover, 1% of patients 
presenting with Cushing’s syndrome have a 
pulmonary carcinoid tumor.15,16 Acro-
megaly from ectopic secretion of growth 
hormone-releasing hormone also has been 
reported in cases of bronchopulmonary 
carcinoid. Thus, ectopic secretion of 
biologically active hormones is not 
uncommon, as these tumors may secrete 
corticotrophin and growth hormone with 
relative frequency. However, carcinoid 
syndrome occurs in greater than 5% of 
patients with these tumors because of the 
relative paucity of serotonin secretion.17 
Radiologically, most bronchial carci-
noids present as abnormal chest x-ray with 
rounded or ovoid perihilar opacities. A CT 
scan provides better resolution of the tumor 
with regard to extent, location, and 
surrounding lymph nodes.18 Extensive 
imaging is important for staging. 
Endosonography can be used to detect 
luminal lesions as small as 2-3 mm in size.  
Bronchoscopic appearance is a pink or 
red vascular mass which is endobronchial 
with intact overlying epithelium.19 They 
appear as smooth, cherry red, polypoid 
endobronchial nodules. Most bronchial 
carcinoids are in a central location within 
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reach of a bronchoscope. The histologic 
diagnosis is made with bronchoscopic 
biopsy. There may be massive hemorrhage 
following endoscopic biopsy due to the 
highly vascular nature of carcinoids.20 
Surgical resection is the preferred 
treatment of bronchopulmonary carcinoid 
tumors in those patients with adequate 
functional pulmonary reserve. In patients 
with relatively small (less than 2 cm), 
localized tumors of the peripheral lung 
parenchyma, conservative resection via a 
wedge or segmental resection results in low 
recurrence rates and excellent long-term 
survival.12,21 Tumors with extensive central 
bronchopulmonary involvement, those with 
large peripheral parenchymal involvement 
(> 2 cm), and atypical carcinoids may 
require more extensive surgical resection 
with a lobectomy or pneumonectomy.12 
Given the significance of nodal involvement 
in long-term prognostic models of 
pulmonary carcinoid disease, systematic 
radical mediastinal lymphadenectomy 
provides an advantage to all patients at the 
time of initial treatment.22 There is no role 
for chemotherapy or radiotherapy in 
treatment of bronchial carcinoid. Palliative 
radiotherapy prior to surgical resection can 
be performed to decrease the tumor burden 
prior to resection.  
Patients with pulmonary carcinoid 
tumors often have a good prognosis, with 5-
year survival rates between 60% and 100% 
and 10-year survival rates between 40% and 
100%.23 Typical bronchial carcinoid tumors 
have the best prognoses with 5-year survival 
of 87 to 100%. Metastases from typical 
pulmonary carcinoids occur in approxi- 
mately 12% of cases, and the overall 
survival rate is greater than 90%.12 
The optimal post-treatment surveillance 
strategy is not defined. There is no 
consensus on what tests should be ordered. 
Most clinicians perform history and physical 
examination and chest CT annually for 
patients with resected typical carcinoid and 
every six months for resected atypical 
carcinoids for the first two years, then 
annually.24 
 
Conclusion 
It is important to keep bronchial 
carcinoid tumor in the differential diagnosis 
of a patient with hemoptysis who is a non-
smoker and has no other risk factors for 
malignancy or infection and is otherwise 
healthy. Also, not all lung tumors have poor 
prognosis. Timely treatment can lead to 
normal life expectancy in an otherwise 
healthy patient.  
 
 
References  
1 Lubarsh O. Uber den pimaeren krebs des 
ileum nebst Bemerkungen ueber das 
gleichzeitige Vorkommen von krebs und 
Tuberculos. Virchows Arch 1888; 11:280-
317. 
2 Ranson WB. Case of primary carcinoma 
of ileum. Lancet 1890; 2:1020. 
3 Obendorfer S. Karzinoide Rumoren des 
Dunndarms. FrankfZ Pathol 1907; 1:425-
429. 
4 Masson P. Carcinoids (argentaffin-cell 
tumors) and nerve hyperplasia  of  append- 
 
 
icular mucosa. Am J Pathol 1928; 
4(3):181-212. PMID: 19969788. 
5 Kramer R. Adenoma of bronchus. Ann 
Otol Rhinol Laryngol 1930; 39:689-675. 
6 Arrigoni MG, Woolner LB, Bernatz PE.  
Atypical carcinoid tumors of the lung. J 
Thorac Cardiovasc Surg 1972; 64(3):413-
417. PMID: 5054879. 
7 Dusmet ME, McKneally MF. Pulmonary 
and thymic carcinoid tumors. World J 
Surg 1996; 20(2):189-95. PMID: 
8661816. 
 
Kansas Journal of Medicine 2013                                          Bronchial Carcinoid 
 
38 
 
8 Modlin IM, Sandor A. An analysis of 
8305  cases  of  carcinoid  tumors.  Cancer 
1997; 79(4):813-829. PMID: 9024720. 
9 Williams ED, Sandlers M. The classi-
fication of carcinoid tumors. Lancet 1963; 
1(7275):238-239. PMID: 14000847. 
10 Granberg D, Sundin A, Janson ET, Oberg 
K, Skogseid B, Westlin JE. Octreoscan in 
patients with bronchial carcinoid tumours. 
Clin Endocrinol (Oxf) 2003; 59(6):793-
799. PMID: 14974924. 
11 Pearse AG. The cytochemistry and 
ultrastructure of polypeptide hormone-
producing cells of the APUD series and 
the embyrologic, physiologic, and 
pathologic implications of the concept. J 
Histochem Cytochem 1969; 17(5):303-
313. PMID: 4143745. 
12 Kulke MH, Mayer RJ. Carcinoid tumors. 
N Engl J Med 1999; 340(11):858-868. 
PMID: 10080850. 
13 Travis WD, Brambilla E, Müller-
Hermelink HK, Harris CC. World Health 
Organization Classification of Tumors. 
Volume 10. Pathology and Genetics of 
Tumours of the Lung, Pleura, Thymus and 
Heart. Lyon, France: IARC Press, 2004.  
14 Campana D, Nori F, Piscitelli L, et al. 
Chromogranin A: Is it a useful marker of 
neuroendocrine tumors? J Clin Oncol 
2007; 25(15):1967-1973. PMID: 175138 
02. 
15 Dusmet M, McKneally MF. Bronchial and 
thymic carcinoid tumors: A review. 
Digestion 1994; 55(Suppl 3):70-76. 
PMID: 7698541. 
16 Wajchenberg BL, Mendonca BB, 
Liberman B, et al. Ectopic adreno-
corticotropic hormone syndrome. Endocr 
Rev 1994; 15(6):752-787. PMID: 
7705280. 
17 Page I, Corcoran A, Vollenfrend S. 
Argentaffinoma as an endocrine tumor. 
Lancet 1955; 1: 198-9.  
18 Nessi R, Basso Ricci P, Basso Ricci S, 
Bosco M, Blanc M, Uslenghi C. Bronchial 
carcinoid tumors: Radiologic observations 
in 49 cases. J Thorac Imaging 1991; 
6(2):47-53. PMID: 1649924.  
19 Jeung MY, Gasser, B, Gangi A, et al. 
Bronchial carcinoid tumors of the thorax: 
Spectrum of radiologic findings. 
Radiographics 2002; 22(2):351-365. 
PMID: 11896225. 
20 Todd TR, Cooper JD, Weissberg D, 
Delarue NC, Pearson FG. Bronchial 
carcinoid tumors: Twenty years’ 
experience. J Thorac Cardiovasc Surg 
1980; 79(4):532-536. PMID: 7359932. 
21 Ferguson MK, Landreneau RJ, Hazelrigg 
SR, et al. Long-term outcome after 
resection for bronchial carcinoid tumors. 
Eur J Cardiothorac Surg 2000; 18(2):156-
161. PMID: 10925223. 
22 García-Yuste M, Matillo JM, Cueto A, et 
al. Typical and atypical carcinoid tumours: 
Analysis of the experience of the Spanish 
Multi-centric Study of Neuroendocrine 
Tumours of the Lung. Eur J Cardiothorac 
Surg 2007; 31(2):192-197. PMID: 
17196822. 
23 Froudarakis M, Fournel P, Burgard G, et 
al. Bronchial carcinoids. A review of 22 
cases. Oncology 1996; 53(2):153-158. 
PMID: 8604242. 
24 National Comprehensive Cancer Network.  
NCCN guidelines. Available at: 
www.nccn.org. Accessed: May 15, 2012.  
 
Keywords: bronchial carcinoma, pulmonary 
neoplasms, hemoptysis, case report 
 
 
 
